Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon‐alfa in hepatitis‐B‐e‐antigen‐positive patients

Chen, Chien‐Hung; Lee, Chuan–Mo; Hung, Chao‐Hung; Wang, Jing‐Houng; Hu, Tsung–Hui; Changchien, Chi‐Sin; Lu, Sheng–Nan

doi:10.1111/j.1440-1746.2010.06429.x

Cited by 14 publications

(18 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV genotypes have been associated with variable clinical outcomes and different responses to IFNα and NRTI treatments that are discussed below (Chien et al, 2003, Hsieh et al, 2009, Chen et al, 2011, Lin and Kao, 2011). Since the S and P gene sequences partially overlap with each other but are translated in different reading frames, single nucleotide changes among different HBV genotypes may or may not affect the amino acid composition of both gene products (Figure 2) (Mizokami et al, 1997).…”

Section: Hbv Serotypes and Genotypesmentioning

confidence: 99%

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Michailidis

Kirby

Hachiya

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is the etiologic agent of mankind’s most serious liver disease. While the availability of a vaccine has reduced the number of new HBV infections, the vaccine does not benefit the approximately 350 million people already chronically infected by the virus. Most of the drugs approved by the FDA for the treatment of hepatitis B target the reverse transcriptase (RT or P gene product) and are nucleoside RT inhibitors (NRTIs) that suppress viral replication. However, prolonged monotherapies directed against a single target result in the emergence of viral resistance. HBV genotypic differences affect NRTI resistance, and because the reading frames of the S (surface antigen) and P genes partially overlap, genomic differences that affect the surface of the virus may also alter the viral polymerase sequence, function and drug susceptibility. The scope of this review is to assess the effects of HBV genotypic variation on the development of drug resistance to NRTIs. Some RT residues that vary among different genotypes are in the vicinity of residues that mutate and give rise to NRTI resistance. Interactions between these amino acids can help explain the effect of HBV genotype on the development of NRTI resistance during antiviral therapies, and might help in the design of improved therapeutic strategies.

show abstract

Section: Hbv Serotypes and Genotypesmentioning

confidence: 99%

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Michailidis

Kirby

Hachiya

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

show abstract

“…Perinatal transmission of HBV is strongly associated with HBeAg positivity in the mother (11) and HBeAg seroconversion is considered as a marker for a sustained therapeutic response (12). Quantitative assays for HBeAg are not routinely available, and HBeAg levels are expressed as serial dilutions of a reference sample from the Paul Ehrlich Institute (Langen, Germany) (13).…”

Section: Introductionmentioning

confidence: 99%

“…Quantitative assays for HBeAg are not routinely available, and HBeAg levels are expressed as serial dilutions of a reference sample from the Paul Ehrlich Institute (Langen, Germany) (13). It has been suggested that the evaluation of the HBeAg sample to cut-off ratio (S/co ratio) could be useful for HBV diagnosis and treatment (12,14).…”

Section: Introductionmentioning

confidence: 99%

Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection

Zeng

Liu

Dong

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract.The association between hepatitis B surface antigen (HBsAg) and hepatitis B 'e' antigen (HBeAg) levels and liver inflammation and fibrosis in patients with chronic hepatitis B (CHB) in the immune clearance (IC) remains elusive. The aim of the present study was to investigate whether HBsAg and HBeAg levels were associated with liver inflammation and fibrosis in CHB patients during the IC phase. Kendall's rank correlation analysis and receiver operating characteristic curves were used to determine the correlation between HBsAg, HBeAg and liver pathological stages. Multivariate analysis by forward logistic regression was used to analyze significant predictors of cirrhosis. A liver pathology-predicting model (IC model), which used routinely assessed markers in combination with HBsAg and HBeAg levels, was constructed. There were significantly positive correlations between the HBsAg and HBeAg levels (γ= 0.317, P<0.001), and between the HBsAg and HBV-DNA levels (γ=0.489, P<0.001). However, there was no correlation between the HBsAg and alanine aminotransferase levels. HBsAg and HBeAg levels differed significantly at various liver pathological stages and declined progressively in advanced liver pathological stages. Multivariate logistic regression analysis showed that age, HBsAg and HBeAg levels as well as the international normalized ratio (INR) were independent predictors of liver fibrosis during the IC phase. The IC model had a specificity and sensitivity of 88.64 and 78.24%, respectively, a positive predictive value of 48.15% and negative predictive value of 96.79%. In conclusion, HBsAg and HBeAg levels were negatively and indirectly correlated with liver inflammation and fibrosis in CHB patients in the IC phase. The IC model reliably predicted the probability of liver cirrhosis.

show abstract

“…Nine studies involving 1855 participants (genotype B group = 802, genotype C group = 1053) reported the rate of sustained ALT normalization. Luo et al .…”

Section: Resultsmentioning

confidence: 99%

“…One review, which evaluated the influence of HBV genotype on the outcome of IFN therapy, has been published before . The review did not include the recent nine studies . An update of the meta‐analysis is needed to provide stronger and more general support the relationship between HBV genotype B and C and response to IFN therapy in HBeAg‐positive CHB patients.…”

Section: Introductionmentioning

confidence: 99%

Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta‐analysis

Kong

Qin

et al. 2014

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon‐alfa in hepatitis‐B‐e‐antigen‐positive patients

Abstract: Pretreatment HBeAg S/Co ratio ≤ 200 and HBV genotype B were major determinants for treatment response to peginterferon. Genotype-B-infected patients had higher probability of delayed HBeAg clearance and sustained response. Rapid decrease of HBeAg titer was useful on treatment predictor.

Cited by 14 publications

References 44 publications

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection

Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta‐analysis

Contact Info

Product

Resources

About